Key Highlights
- First-quarter adjusted EPS reached $2.57, surpassing the Street’s $2.18 expectation and extending the company’s winning streak to five quarters
- Quarterly revenue totaled $100.4 billion, significantly exceeding Wall Street’s $95 billion projection
- Aetna’s medical benefit ratio dropped to 84.6%, a notable improvement from last year’s 87.3%
- Annual 2026 adjusted EPS forecast upgraded to $7.30–$7.50 range, above the prior $7.00–$7.20 outlook
- Shares advanced 4.9% during premarket hours on the earnings announcement
CVS Health shares experienced a 4.9% premarket surge on Wednesday following robust first-quarter performance and an upward revision to its annual forecast.
The pharmacy giant delivered adjusted profit of $2.57 per share, comfortably exceeding analyst projections of $2.18. Total revenue reached $100.4 billion, substantially higher than the $95 billion anticipated by market watchers.
The results represent CVS’s fifth consecutive quarter of earnings outperformance. Management has maintained a conservative stance on projections while implementing restructuring efforts following challenges experienced throughout 2024.
CVS elevated its full-year 2026 adjusted EPS projection to between $7.30 and $7.50, representing an increase from the previous $7.00 to $7.20 range. The healthcare company also boosted its operating cash flow target to a minimum of $9.5 billion from at least $9 billion previously.
Prior to Wednesday’s announcement, the stock had advanced only 1.7% year-to-date, underperforming the S&P 500’s 6% climb.
Aetna Division Shows Margin Strength
The most impressive metric came from the medical benefit ratio within its Aetna insurance business. The figure registered at 84.6%, substantially below analyst expectations of 87.58% and representing a decline from the previous year’s 87.3%.
This metric represents the portion of premium collections allocated to medical care expenses. Lower figures indicate stronger profitability for insurers. CFO Brian Newman attributed the enhancement to superior forecasting capabilities and effective expense management.
Both UnitedHealth and Humana similarly exceeded projections on this measure during the first quarter, suggesting widespread enhancement throughout the Medicare Advantage sector.
Federal authorities announced in April a 2.48% average increase to 2027 Medicare Advantage reimbursement rates. Newman noted this adjustment remains insufficient relative to anticipated expense growth for the coming year, potentially requiring CVS to modify pricing structures or coverage offerings.
PBM Division Grows While Retail Pharmacy Faces Headwinds
The health services division, which encompasses the Caremark pharmacy benefit management operation, reported revenue growth of 11% to $48.2 billion. Operating profit totaled $1.34 billion, matching analyst forecasts.
Newman credited an enhanced drug mix for supporting Caremark’s financial performance. Leerink analyst Michael Cherny had previously identified the $1.3 billion adjusted operating income threshold for this segment as crucial for rebuilding market confidence.
Pharmacy benefit managers continue facing scrutiny from government officials and regulatory bodies regarding medication pricing mechanisms. CVS faces a pending FTC settlement concerning claims that its PBM artificially elevated insulin costs, accusations the corporation disputes.
The company is also challenging Tennessee legislation that would prohibit PBMs from operating pharmacies within state borders. The measure has cleared the state legislature and awaits the governor’s decision.
The retail pharmacy division delivered 5% revenue growth in 2025 following the integration of former Rite Aid locations, which brought 9 million additional customers. However, operating profit for this segment declined 8.8% compared to the prior-year quarter.
CVS pointed to regulatory modifications affecting specific medication prices, reduced cold and flu season activity, and weather-related disruptions — including temporary store closures from snowstorms — as factors pressuring pharmacy operations.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
